Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
SAN FRANCISCO and SUZHOU, China, July 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent Biologics' Artificial Intelligence for Drug Discovery platform . Through this collaboration, both parties will combine their respective strengths and technologies to further accelerate the drug discovery and development process using AI technology.
因塞特生物医药(Innovent)(香港交易所:01801)是一家世界一流的生物制药公司,致力于开发、制造和商业化用于治疗肿瘤、心血管和代谢性疾病、自身免疫性疾病、眼科医疗以及其他重大疾病的高质量药物。今天宣布与WeComput达成战略合作伙伴关系,共同推进因塞特生物制品的药物发现平台的建设和改进人工智能。通过这一合作,双方将结合各自的优势和技术,进一步加速使用人工智能技术的药物发现和开发过程。
As an important R&D engine of Innovent, Innovent Academy has been deeply exploring and actively deploying AI drug research and development. In this collaboration, Innovent Academy will utilize WeComput's WeMol, a molecular design platform, to build and enhance its computing infrastructure, accelerating the drug research and development process. Meanwhile, WeMol will integrate NVIDIA's BioNeMo to further expand the computing capability of Innovent's AI systems and improve computational efficiency.
因诺维学院作为因塞特的一种重要的研发引擎,一直在深入探索和积极部署人工智能药物研究和开发。在这项合作中,因诺维学院将利用WeComput的分子设计平台WeMol来构建和增强其计算基础设施,加速药物研究和开发过程,同时,WeMol将集成英伟达的BioNeMo来进一步扩大因塞特的AI系统的计算能力,提高计算效率。
Innovent and WeMol will integrate their technological strengths to create a comprehensive AI-driven drug discovery and development system that is efficient, user-friendly, digitalized, intelligent and automated. This cooperation will allow Innovent to significantly reduce AI implementation and experimental costs, shorten the drug R&D cycle, improve R&D success rate, and deliver more innovative drugs and treatment options to patients.
因塞特和WeMol将整合各自的技术优势,创建一个全面的基于人工智能的药物发现和开发系统,高效、用户友好、数字化、智能和自动化。这种合作将使因塞特大幅降低人工智能实施数和实验成本,缩短药物研发周期,提高研发成功率,为患者提供更多创新药物和治疗选择。
Dr. Kaijie He, Vice President of Oncology Biology and ADC Drug Research, said, "AI is injecting new momentum into the global pharmaceutical and biotech industries. We are excited to partner with WeComput and integrate advanced AI technology to boost our R&D capabilities and expedite the discovery and development of innovative drugs. We believe this collaboration will offer robust technical support to our research team, propelling us toward greater breakthroughs in the global pharmaceutical market."
肿瘤生物学与ADC药物研究副总裁何凯杰博士表示:“人工智能正在为全球制药和生物技术行业注入新的动力。我们很高兴能与WeComput合作,整合先进的人工智能技术,提升我们的研发能力,加速创新药物的发现和开发。我们相信,这种合作将为我们的研究团队提供强有力的技术支持,并推动我们在全球制药市场上取得更大的突破。”
Harry (Hu) Ge, CEO of WeComput, stated, "This collaboration will be mutually beneficial, fostering the widespread application of AI technology in the biopharmaceutical sector and driving innovation and development in the global pharmaceutical industry."
WeComput的首席执行官Harry(胡)Ge表示:“这种合作将是互惠互利的,促进人工智能技术在生物制药领域的广泛应用,并推动全球制药产业的创新和发展。”
About Innovent Biologics
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 10 products in the market. It has 4 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.
关于因塞特生物医药
因塞特是一家领先的生物制药公司,成立于2011年,其使命是为全球患者提供价格实惠、高质量的生物制药。该公司发现、开发、制造和商业化针对一些顽疾的创新药物,包括肿瘤、心血管和代谢性疾病、自身免疫性疾病和眼科疾病。因塞特已经在市场上推出了10款产品。其有4个新药申请正在接受监管审查,有4个资产处于III期或关键临床试验阶段,还有18种化合物处于早期临床阶段。因塞特与全球30多家医疗保健企业合作,包括礼来、赛诺菲、因塞特、Adimab、LG Chem和MD Anderson癌症中心。
Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn.
康德新的座右铭是“始于诚信,成功于行动”,保持着业界最高的行业标准,致力于推动生物制药行业的发展,使一流的制药产品成为广泛可及的。有关更多信息,请访问或在Facebook和LinkedIn上关注康德新。
About WeComput
WeComput is dedicated to "computational technology driving innovative drug research and development." With a profound understanding of the innovative drug development process, WeComput integrates artificial intelligence, biophysics, and high-performance computing technologies to create a unique digital, intelligent and automated platform for drug molecule generation, design and simulation. This platform is poised to revolutionize traditional drug discovery methods and drive the research and development of innovative drugs such as antibodies, proteins, small molecules and mRNA. The parent company, Beijing Zhongda Weixin Technology Co., Ltd., was registered in 2015 and has been recognized as a national high-tech enterprise. In 2021, it received equity investment from Sequoia Capital and was selected as a senior member of the NVIDIA Inception program. To date, WeComput has served hundreds of clients worldwide, including numerous biopharmaceutical companies, universities, hospitals, and research institutions, and has independently developed the leading drug molecule design and intelligent computing platform, WeMol.
关于WeComput
WeComput致力于“计算技术推动创新药物研究和开发”。WeComput凭借对创新药物开发过程的深刻理解,整合了人工智能、生物物理学和高性能计算技术,创建了一个独特的数字化、智能和自动化平台,用于药物分子的生成、设计和模拟。该平台有望彻底改变传统的药物发现方法,并推动抗体、蛋白质、小分子和mRNA等创新药物的研究和开发。母公司北京中大微信科技有限公司成立于2015年,并获得国家高新技术企业认定。2021年,它获得了红杉资本的股权投资,并被选为英伟达创业计划的高级成员。截至目前,WeComput已为全球数百个客户提供服务,包括许多生物制药公司、高校、医院和研究机构,并独立开发了领先的药物分子设计和智能计算平台WeMol。
SOURCE Innovent Biologics
来源于康泰生物制品